Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)

被引：0
|
作者：
Piulats Rodriguez, M. [1 ]
de la Cruz-Merino, L. [2 ]
Espinosa, E. [3 ]
Alonso Carrion, L. [4 ]
Martin Algarra, S. [5 ]
Lopez-Castro, R. [6 ]
Curiel Garcia, M. T. [7 ]
Rodriguez Abreu, D. [8 ]
Rullan Iriarte, A. J. [9 ]
Berrocal Jaime, A. [10 ]
机构：
[1] ICO, Med Oncol, Barcelona, Spain
[2] Hosp Univ Virgen Macarena, Oncol, Seville, Spain
[3] Hosp Univ La Paz, Oncol, Madrid, Spain
[4] Univ Malaga, Oncol, Malaga, Spain
[5] Clin Univ Navarra, Oncol, Navarra, Spain
[6] Hosp Univ Clin Valladolid, Med Oncol, Valladolid, Spain
[7] Hosp Univ Clin Santiago, Oncol, Santiago De Compostela, Spain
[8] Hosp Insular Canarias, Oncol, Las Palmas Gran Canaria, Spain
[9] Inst Catala Oncol, Oncol, Barcelona, Spain
[10] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1247PD
引用
收藏
页码：444 / 444
页数：1
相关论文
共 50 条
  • [41] A single-arm, open-label, multicenter phase II trial (CheckMate 172) of nivolumab (NIVO) safety in European patients (pts) with advanced melanoma (MEL) who have progressed after ipilimumab therapy (IPI).
    Schadendorf, Dirk
    Ascierto, Paolo Antonio
    Espinosa, Enrique
    Haanen, John B. A. G.
    Hermann, Frank
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
    Amin, Asim
    Lawson, David H.
    Salama, April K. S.
    Koon, Henry B.
    Guthrie, Troy, Jr.
    Thomas, Sajeve S.
    O'Day, Steven J.
    Shaheen, Montaser F.
    Zhang, Bin
    Francis, Stephen
    Hodi, F. Stephen
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [43] Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC
    Omar Kaseb, Ahmed
    Duda, Dan G.
    Tran Cao, Hop Sanderson
    Abugabal, Yehia I.
    Vence, Luis M.
    Rashid, Asif
    Pestana, Roberto
    Blando, Jorge M.
    Singh, Shalini
    Vauthey, Jean-Nicolas
    Hassan, Manal
    Amin, Hesham M.
    Qayyum, Aliya
    Shin Chun, Yun
    David Tzeng, Ching-Wei
    Sakamuri, Divya
    Wolff, Robert A.
    Yao, James C.
    Patrick Allison, James
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [44] NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).
    Lutzky, Jose
    Feun, Lynn G.
    Magallanes, Norma
    Kwon, Deukwoo
    Harbour, J. William
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [45] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Song, Zhengbo
    Lou, Guangyuan
    Wang, Yina
    Yang, Zhiping
    Wang, Wenxian
    Ji, Yongling
    Chen, Shiqing
    Xu, Chunwei
    Hu, Xiao
    Zhang, Yiping
    BMC MEDICINE, 2022, 20 (01)
  • [46] ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
    Zager, Jonathan S.
    Orloff, Marlana
    Ferrucci, Pier Francesco
    Choi, Junsung
    Eschelman, David J.
    Glazer, Evan S.
    Ejaz, Aslam
    Howard, J. Harrison
    Richtig, Erika
    Ochsenreither, Sebastian
    Reddy, Sunil A.
    Lowe, Michael C.
    Beasley, Georgia M.
    Gesierich, Anja
    Bender, Armin
    Gschnell, Martin
    Dummer, Reinhard
    Rivoire, Michel
    Arance, Ana
    Fenwick, Stephen William
    Sacco, Joseph J.
    Haferkamp, Sebastian
    Weishaupt, Carsten
    John, Johnny
    Wheater, Matthew
    Ottensmeier, Christian H.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5220 - 5221
  • [47] Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
    Zhengbo Song
    Guangyuan Lou
    Yina Wang
    Zhiping Yang
    Wenxian Wang
    Yongling Ji
    Shiqing Chen
    Chunwei Xu
    Xiao Hu
    Yiping Zhang
    BMC Medicine, 20
  • [48] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [49] Phase II single-arm multi-center study of adjuvant ipilimumab in combination with nivolumab in subjects with high-risk ocular melanoma.
    Rapisuwon, Suthee
    Patel, Sapna Pradyuman
    Carvajal, Richard D.
    Hernandez-Aya, Leonel Fernando
    Tsai, Katy K.
    Chandra, Sunandana
    Tan, Ming Tony
    Daud, Adil
    Sosman, Jeffrey Alan
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma.
    Hersh, EM
    O'Day, S
    Gonzalez, R
    Samlowski, WE
    Gordon, MS
    Hawkins, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 724S - 724S
12345